Question special
Moderator

To piggyback off of Morgan's question about treatment duration, a question about treatment initiation:
In these trials mepolizumab was used as an adjunctive therapy for patients with COPD exacerbations already on triple inhaled therapy. Might there be a role for using anti-IL5 therapy earlier in the treatment course for patients with COPD and an eosinophilic phenotype?